Verrica’s Full Phase III Dataset In Molluscum Shows Greater Separation From Placebo
Executive Summary
The latest Phase III data on Verrica’s formulation of cantharidin for the skin disease molluscum show a wider disparity from placebo.
You may also be interested in...
Verrica Finally Gets Molluscum Treatment To The Finish Line
Verrica’s Ycanth, a drug-device combination product containing a formulation of cantharidin, is approved by the FDA as the first treatment for molluscum, after three complete response letters.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102
After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.